Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888484 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL12663220 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL29881025 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL1769434 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL12527408 | 0.80 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTPDK2PIK3CA | |
| SCHEMBL13651528 | 0.80 | — | — | |
| SCHEMBL15533835 | 0.80 | EGLN2 (0.57) | ALDH1A1LMNAMAPTEGLN2PDK2 | |
| SCHEMBL29509737 | 0.78 | MAPT (0.53) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL4721986 | 0.78 | MAPT (0.53) | ALDH1A1LMNAMAPTPDK2GPR119 | |
| SCHEMBL1886952 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2244577-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8273737-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2244577-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094279-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | ALDH1A1 1850/4885LMNA 3772/4885MAPT 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.